vs
BXP, Inc.（BXP）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
BXP, Inc.的季度营收约是Medpace Holdings, Inc.的1.2倍（$872.1M vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs 15.3%，领先3.8%），Medpace Holdings, Inc.同比增速更快（32.0% vs 0.8%），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 1.3%）
BXP是美国头部商业地产投资信托企业，核心业务为持有、运营及开发A级高端写字楼资产，项目覆盖纽约、波士顿、旧金山等美国核心都市圈，服务企业、科技、专业服务等领域的多元租户。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
BXP vs MEDP — 直观对比
营收规模更大
BXP
是对方的1.2倍
$708.5M
营收增速更快
MEDP
高出31.2%
0.8%
净利率更高
MEDP
高出3.8%
15.3%
两年增速更快
MEDP
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $872.1M | $708.5M |
| 净利润 | $133.0M | $135.1M |
| 毛利率 | — | — |
| 营业利润率 | — | 21.6% |
| 净利率 | 15.3% | 19.1% |
| 营收同比 | 0.8% | 32.0% |
| 净利润同比 | 53.0% | 15.5% |
| 每股收益（稀释后） | $1.69 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXPMEDP
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $708.5M | ||
| Q3 25 | $871.5M | $659.9M | ||
| Q2 25 | $868.5M | $603.3M | ||
| Q1 25 | $865.2M | $558.6M | ||
| Q4 24 | $858.6M | $536.6M | ||
| Q3 24 | $859.2M | $533.3M | ||
| Q2 24 | $850.5M | $528.1M |
净利润BXPMEDP
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $135.1M | ||
| Q3 25 | $-121.7M | $111.1M | ||
| Q2 25 | $89.0M | $90.3M | ||
| Q1 25 | $61.2M | $114.6M | ||
| Q4 24 | $-228.9M | $117.0M | ||
| Q3 24 | $83.6M | $96.4M | ||
| Q2 24 | $79.6M | $88.4M |
毛利率BXPMEDP
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | — | ||
| Q3 25 | 59.3% | — | ||
| Q2 25 | 59.2% | — | ||
| Q1 25 | 59.2% | — | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 59.5% | — | ||
| Q2 24 | 59.8% | — |
营业利润率BXPMEDP
| Q1 26 | — | — | ||
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 21.1% | ||
| Q2 24 | — | 19.9% |
净利率BXPMEDP
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | 19.1% | ||
| Q3 25 | -14.0% | 16.8% | ||
| Q2 25 | 10.2% | 15.0% | ||
| Q1 25 | 7.1% | 20.5% | ||
| Q4 24 | -26.7% | 21.8% | ||
| Q3 24 | 9.7% | 18.1% | ||
| Q2 24 | 9.4% | 16.7% |
每股收益（稀释后）BXPMEDP
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $4.65 | ||
| Q3 25 | $-0.77 | $3.86 | ||
| Q2 25 | $0.56 | $3.10 | ||
| Q1 25 | $0.39 | $3.67 | ||
| Q4 24 | $-1.46 | $3.67 | ||
| Q3 24 | $0.53 | $3.01 | ||
| Q2 24 | $0.51 | $2.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $512.8M | $497.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.7B | $459.1M |
| 总资产 | $25.1B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BXPMEDP
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $497.0M | ||
| Q3 25 | $861.1M | $285.4M | ||
| Q2 25 | $447.0M | $46.3M | ||
| Q1 25 | $398.1M | $441.4M | ||
| Q4 24 | $1.3B | $669.4M | ||
| Q3 24 | $1.4B | $656.9M | ||
| Q2 24 | $685.4M | $510.9M |
股东权益BXPMEDP
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $459.1M | ||
| Q3 25 | $5.0B | $293.6M | ||
| Q2 25 | $5.3B | $172.4M | ||
| Q1 25 | $5.3B | $593.6M | ||
| Q4 24 | $5.4B | $825.5M | ||
| Q3 24 | $5.8B | $881.4M | ||
| Q2 24 | $5.8B | $763.6M |
总资产BXPMEDP
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $2.0B | ||
| Q3 25 | $26.0B | $1.8B | ||
| Q2 25 | $25.6B | $1.6B | ||
| Q1 25 | $25.4B | $1.9B | ||
| Q4 24 | $26.1B | $2.1B | ||
| Q3 24 | $26.4B | $2.1B | ||
| Q2 24 | $25.5B | $1.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $192.7M |
| 自由现金流经营现金流 - 资本支出 | — | $188.1M |
| 自由现金流率自由现金流/营收 | — | 26.6% |
| 资本支出强度资本支出/营收 | 1.5% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.43× |
| 过去12个月自由现金流最近4个季度 | — | $681.9M |
8季度趋势，按日历期对齐
经营现金流BXPMEDP
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $192.7M | ||
| Q3 25 | $274.2M | $246.2M | ||
| Q2 25 | $353.1M | $148.5M | ||
| Q1 25 | $210.0M | $125.8M | ||
| Q4 24 | $383.7M | $190.7M | ||
| Q3 24 | $286.1M | $149.1M | ||
| Q2 24 | $367.1M | $116.4M |
自由现金流BXPMEDP
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $188.1M | ||
| Q3 25 | $231.6M | $235.5M | ||
| Q2 25 | $281.5M | $142.4M | ||
| Q1 25 | $152.6M | $115.8M | ||
| Q4 24 | $312.5M | $183.0M | ||
| Q3 24 | $234.5M | $138.5M | ||
| Q2 24 | $332.4M | $103.5M |
自由现金流率BXPMEDP
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 26.6% | ||
| Q3 25 | 26.6% | 35.7% | ||
| Q2 25 | 32.4% | 23.6% | ||
| Q1 25 | 17.6% | 20.7% | ||
| Q4 24 | 36.4% | 34.1% | ||
| Q3 24 | 27.3% | 26.0% | ||
| Q2 24 | 39.1% | 19.6% |
资本支出强度BXPMEDP
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 0.6% | ||
| Q3 25 | 4.9% | 1.6% | ||
| Q2 25 | 8.2% | 1.0% | ||
| Q1 25 | 6.6% | 1.8% | ||
| Q4 24 | 8.3% | 1.4% | ||
| Q3 24 | 6.0% | 2.0% | ||
| Q2 24 | 4.1% | 2.4% |
现金转化率BXPMEDP
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 3.97× | 1.65× | ||
| Q1 25 | 3.43× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | 3.42× | 1.55× | ||
| Q2 24 | 4.61× | 1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
